Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.

COVID-19 antihistamine chemoinformatics drug repurposing high-throughput screening phenothiazine prophylaxis

Journal

Advances and applications in bioinformatics and chemistry : AABC
ISSN: 1178-6949
Titre abrégé: Adv Appl Bioinform Chem
Pays: New Zealand
ID NLM: 101550215

Informations de publication

Date de publication:
2021
Historique:
received: 30 01 2021
accepted: 04 03 2021
entrez: 21 4 2021
pubmed: 22 4 2021
medline: 22 4 2021
Statut: epublish

Résumé

There is an urgent need to identify therapies that prevent SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Based upon clinical observations, we proposed that some psychotropic and antihistaminic drugs could protect psychiatric patients from SARS-CoV-2 infection. This observation is investigated in the light of experimental in vitro data on SARS-CoV-2. SARS-CoV-2 high-throughput screening results are available at the NCATS COVID-19 portal. We investigated the in vitro anti-viral activity of many psychotropic and antihistaminic drugs using chemoinformatics approaches. We analyze our clinical observations in the light of SARS-CoV-2 experimental screening results and propose that several cationic amphiphilic psychotropic and antihistaminic drugs could protect people from SARS-CoV-2 infection; some of these molecules have very limited adverse effects and could be used as prophylactic drugs. Other cationic amphiphilic drugs used in other disease areas are also highlighted. Recent analyses of patient electronic health records reported by several research groups indicate that some of these molecules could be of interest at different stages of the disease progression. In addition, recently reported drug combination studies further suggest that it might be valuable to associate several cationic amphiphilic drugs. Taken together, these observations underline the need for clinical trials to fully evaluate the potentials of these molecules, some fitting in the so-called category of broad-spectrum antiviral agents. Repositioning orally available drugs that have moderate side effects and should act on molecular mechanisms less prone to drug resistance would indeed be of utmost importance to deal with COVID-19.

Identifiants

pubmed: 33880039
doi: 10.2147/AABC.S304649
pii: 304649
pmc: PMC8051956
doi:

Types de publication

Journal Article

Langues

eng

Pagination

71-85

Informations de copyright

© 2021 Villoutreix et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest for this work nor any competing financial interests or personal relationships that could influence the work reported in this paper.

Références

JAMA. 2020 Dec 8;324(22):2292-2300
pubmed: 33180097
Int J Mol Sci. 2021 Feb 08;22(4):
pubmed: 33567580
Clin Drug Investig. 2021 Mar;41(3):221-233
pubmed: 33559821
Pharmaceuticals (Basel). 2020 Dec 04;13(12):
pubmed: 33291642
Travel Med Infect Dis. 2020 Sep - Oct;37:101874
pubmed: 32891724
Nat Commun. 2021 Feb 8;12(1):844
pubmed: 33558507
ACS Pharmacol Transl Sci. 2020 Oct 09;3(6):1265-1277
pubmed: 33330841
ACS Infect Dis. 2020 Dec 21;:
pubmed: 33346633
Int J Infect Dis. 2020 Apr;93:268-276
pubmed: 32081774
J Virol. 2020 Oct 14;94(21):
pubmed: 32817221
Med Hypotheses. 2021 Mar;148:110508
pubmed: 33571758
Biomed Pharmacother. 2020 Oct;130:110582
pubmed: 32763818
Nucleic Acids Res. 2021 Jan 8;49(D1):D1388-D1395
pubmed: 33151290
Int J Antimicrob Agents. 2021 Mar;57(3):106274
pubmed: 33387629
Pharmaceutics. 2021 Jan 09;13(1):
pubmed: 33435273
J Chem Inf Model. 2021 Jan 25;61(1):26-35
pubmed: 33382611
J Chem Inf Model. 2016 Dec 27;56(12):2292-2297
pubmed: 28024397
Nucleic Acids Res. 2021 Jan 8;49(D1):D1160-D1169
pubmed: 33151287
Theranostics. 2020 Jun 12;10(16):7448-7464
pubmed: 32642005
Biochem Biophys Res Commun. 2021 Jan 29;538:173-179
pubmed: 33309272
Chem Soc Rev. 2020 Jun 7;49(11):3525-3564
pubmed: 32356548
Nat Biotechnol. 2021 Feb 23;:
pubmed: 33623157
Brief Bioinform. 2021 Mar 22;22(2):1790-1818
pubmed: 32187356
Front Oncol. 2020 Oct 19;10:562196
pubmed: 33194631
Prog Clin Biol Res. 1989;291:167-71
pubmed: 2726840
PLoS Comput Biol. 2020 Dec 31;16(12):e1008489
pubmed: 33382685
Drug Discov Today. 2015 Mar;20(3):296-300
pubmed: 25449657
Front Pharmacol. 2020 Dec 16;11:577678
pubmed: 33390948
ACS Med Chem Lett. 2018 Jan 29;9(3):204-209
pubmed: 29541361
Life Sci. 2021 Feb 1;266:118889
pubmed: 33310043
Expert Rev Anti Infect Ther. 2017 May;15(5):483-492
pubmed: 28286997
Antiviral Res. 2020 Oct;182:104902
pubmed: 32739404
Nature. 2021 Mar;591(7848):92-98
pubmed: 33307546
Emerg Microbes Infect. 2020 Dec;9(1):2245-2255
pubmed: 32975484
Am J Med Sci. 2020 Sep;360(3):300
pubmed: 32631576
J Cheminform. 2016 Nov 4;8:61
pubmed: 27867422
J Infect Dis. 2018 Nov 22;218(suppl_5):S588-S591
pubmed: 29982632
Biol Chem. 2019 Dec 18;401(1):31-46
pubmed: 31408430
Front Pharmacol. 2021 Jan 13;11:600372
pubmed: 33519460
Med Res Rev. 2021 May;41(3):1375-1426
pubmed: 33277927
FASEB J. 2020 Jun;34(6):7253-7264
pubmed: 32367579
Nucleic Acids Res. 2019 Jan 8;47(D1):D930-D940
pubmed: 30398643
Bioinformatics. 2017 Nov 15;33(22):3658-3660
pubmed: 28961788
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Encephale. 2020 Jun;46(3):169-172
pubmed: 32425222
Drug Discov Today. 2016 Jul;21(7):1189-95
pubmed: 27240777
Sci Rep. 2017 Apr 11;7:46277
pubmed: 28397808
Comput Biol Med. 2020 Nov;126:104051
pubmed: 33131530
Travel Med Infect Dis. 2020 Sep - Oct;37:101873
pubmed: 32916297
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33597253
Life Sci. 2020 Aug 1;254:117775
pubmed: 32418894
Mol Psychiatry. 2021 Feb 4;:
pubmed: 33536545
Leukemia. 2020 Nov;34(11):3085-3087
pubmed: 32999432
J Chem Inf Model. 2015 Feb 23;55(2):460-73
pubmed: 25558886
Med Hypotheses. 2020 Nov;144:110025
pubmed: 33254478
Drug Discov Today. 2020 Aug;25(8):1287-1290
pubmed: 32593662
Psychiatry Res. 2020 Sep;291:113220
pubmed: 32540682
Inform Med Unlocked. 2020;21:100446
pubmed: 33052313
Pulm Pharmacol Ther. 2021 Apr;67:101989
pubmed: 33465426
Front Pharmacol. 2021 Feb 05;11:609592
pubmed: 33613282
Drug Discov Today. 2020 May;25(5):928-941
pubmed: 32320852
Drug Discov Today. 2021 Feb 10;:
pubmed: 33581321
Lancet Infect Dis. 2020 Sep;20(9):1012-1013
pubmed: 32251638
Int J Mol Sci. 2020 Jul 13;21(14):
pubmed: 32668803
Br J Pharmacol. 2020 Nov;177(21):4971-4974
pubmed: 32639031
Lancet Infect Dis. 2003 Nov;3(11):722-7
pubmed: 14592603
Int J Biol Sci. 2021 Jan 1;17(1):97-106
pubmed: 33390836
Eur J Pharmacol. 2020 Nov 15;887:173553
pubmed: 32949606
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082
pubmed: 29126136
ChemMedChem. 2012 Nov;7(11):1925-34
pubmed: 22945602
Eur Respir J. 2021 Jan 14;:
pubmed: 33361100
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Front Immunol. 2020 Jul 02;11:1409
pubmed: 32714335
Pulm Pharmacol Ther. 2020 Aug;63:101942
pubmed: 32871242
J Chem Inf Model. 2020 Dec 28;60(12):5727-5729
pubmed: 32914973

Auteurs

Bruno O Villoutreix (BO)

INSERM U1141, NeuroDiderot, Université de Paris, Hôpital Robert-Debré, Paris, F-75019, France.

Rajagopal Krishnamoorthy (R)

Université Paris Est Créteil, INSERM U955, IMRB, Laboratoire Neuropsychiatrie Translationnelle, AP-HP, Département Medico-Universitaire de Psychiatrie et d'Addictologie (DMU ADAPT), Hôpital Henri Mondor, Fondation FondaMental, Créteil, F-94010, France.

Ryad Tamouza (R)

Université Paris Est Créteil, INSERM U955, IMRB, Laboratoire Neuropsychiatrie Translationnelle, AP-HP, Département Medico-Universitaire de Psychiatrie et d'Addictologie (DMU ADAPT), Hôpital Henri Mondor, Fondation FondaMental, Créteil, F-94010, France.

Marion Leboyer (M)

Université Paris Est Créteil, INSERM U955, IMRB, Laboratoire Neuropsychiatrie Translationnelle, AP-HP, Département Medico-Universitaire de Psychiatrie et d'Addictologie (DMU ADAPT), Hôpital Henri Mondor, Fondation FondaMental, Créteil, F-94010, France.

Philippe Beaune (P)

INSERM U1138, Centre de Recherche des Cordeliers, Université de Paris, Paris, 75006, France.

Classifications MeSH